VEGFA and colorectal carcinoma: Though the use of ICIs can activate an effective antitumor immune response for CMS1 but not for CMS4 CRC subtypes [12], nonetheless, strategies aiming at targeting the TGF-β and/or VEGF pathways might prove useful for CMS4 CRC [27,28].